Authors TheMarket🐝

7 days 30 days All time Recent Popular
@LaurusLabs #lauruslabs #Q3marketupdates #Q3investorpresentations
Q3fy21/20 in crs
Rev 1288/730 ,up 76%
Ebidta 433/150
PAT 273/73 ,up 274%
EPS 5.1/1.4

Generic API growth 103% yoy
ARVs up 175% yoy
Generic FDF up 47%
Custom synthesis up 63% yoy
Onco API growth 36%


Generic APIs
ARV,Anti-DM,CVS,PPIs,Onco
Commercialized 60+ products
61 DMFs filed

Generic FDF
ARV,Anti-DM,CVS,PPIs,Onco
Filed 26 ANDAs with USFDA
9 final & 8 tentative approvals
Filed 12 dossiers in Canada, 9 in EU ,8 with WHO,2 in
https://t.co/Q35cgK2hvy, 2 in India

Laurus Synthesis
CDMO services for Global pharma
Steroids,hormone mftg
Speciality ingredients in Nutraceuticals,dietary,cosmetics

Commercial scale mfg,clinical phase supplies,Analytics & research

API validation plannd in Unit 5
Optalmic initiated
LSPL-API validatn planned


Revenue breakup in crs
Q3fy21/20
Generic API 731/360
Generic FDF 430/292
Synthesis 127/78

Generic API
ARV 568/214
Onco 64/47
Other 99/99

Generic FDF 430/292

Entered in longterm partnership with leading generic player in EU for contract mfg

Synthesis CDMO 127/78 crs


Synthesis CDMO
Revenue from custom synthesis, strong growth 63% yoy
Total active projects in CDMO stood at 49 in Q3
Partnered Large global pharma & mid ,small biotech companies
Commercial supplies ongoing for 4 products